Price (delayed)
$15.76
Market cap
$1.04B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.49
Enterprise value
$737.6M
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed
There are no recent dividends present for COGT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.